US Patent

US10945950 — Liquid inhalation formulation comprising RPL554

Formulation · Assigned to Verona Pharma Ltd · Expires 2035-09-15 · 9y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a liquid inhalation formulation containing RPL554 or a pharmaceutically acceptable salt thereof.

USPTO Abstract

The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation which comprises a diluent and a suspension of particles of 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554) or a pharmaceutically acceptable salt thereof. Also described is a liquid pharmaceutical composition according to the invention for use in the treatment of the human or animal body.

Drugs covered by this patent

Patent Metadata

Patent number
US10945950
Jurisdiction
US
Classification
Formulation
Expires
2035-09-15
Drug substance claim
No
Drug product claim
Yes
Assignee
Verona Pharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.